Wednesday, January 30, 2013 10:48:02 PM
http://www.clinicaltrials.gov/ct2/show/NCT01272791?term=Bavituximab+OR+Peregrine&rank=1
Inclusion criteria.
Patients with histologically or cytologically documented stage IV ductal adenocarcinoma of the pancreas
In addition from the AACR poster presented last year we have this
So the treatment arm in the bavi pancreatic trial has worse PS scores than the control arm,
with 4 patients left to enroll, which will handicap the treatment arm. Then remember these too.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83914184
Recent CDMO News
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
